Search research articles
Contact Us
Filters
Showing results (1-10 of 43) with videos related to
Page
of 5
Sort By:
JAMA Neurology
|
May 31, 2017
Confusing Terminology-Neuroleptic Malignant Syndrome vs Malignant Hyperthermia-Reply
Philippe Damier, Jasem Al-Hashel
JAMA Neurology
|
December 28, 2016
Recommendations for the Treatment of Patients With Parkinson Disease During Ramadan
Philippe Damier, Jasem Al-Hashel
Case Reports in Neurology
|
April 18, 2022
Late-Onset Pompe Disease Presenting with Isolated Tongue Involvement
Jasem Al-Hashel, Ismail Ismail
Multiple Sclerosis and Related Disorders
|
February 2, 2025
Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for Multiple Sclerosis: An observational registry-based study
Raed Alroughani, Jasem Al-Hashel, Samar Farouk Ahmed
Pediatric Neurology
|
September 19, 2015
Pediatric-Onset Multiple Sclerosis Disease Progression in Kuwait: A Retrospective Analysis
Raed Alroughani, Samar F Ahmed, Jasem Al-Hashel
Clinical Neurology and Neurosurgery
|
March 21, 2024
Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study
Raed Alroughani, Jasem Al-Hashel, Samar Farouk Ahmed
Neuroepidemiology
|
August 22, 2008
The prevalence of multiple sclerosis in the Middle East
Jasem Al-Hashel, Aaron D Besterman, Christina Wolfson
Multiple Sclerosis and Related Disorders
|
February 8, 2018
A longitudinal study of JC virus serostatus stability among multiple sclerosis patients
Raed Alroughani, Saeed Akhtar, Samar Ahmed, et al.
Case Reports in Neurological Medicine
|
May 14, 2014
An adult patient with ocular myasthenia and unusually long spontaneous remission
Jasem Al-Hashel, Hanaa M Rashad, Rossen T Rousseff
Multiple Sclerosis and Related Disorders
|
August 26, 2023
Real world study of ocrelizumab in multiple sclerosis: Kuwait experience
Raed Alroughani, Malak AlMojel, Jasem Al-Hashel, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 43) with videos related to
Sort By:
Page
of 5
JAMA Neurology
|
May 31, 2017
Confusing Terminology-Neuroleptic Malignant Syndrome vs Malignant Hyperthermia-Reply
Philippe Damier, Jasem Al-Hashel
JAMA Neurology
|
December 28, 2016
Recommendations for the Treatment of Patients With Parkinson Disease During Ramadan
Philippe Damier, Jasem Al-Hashel
Case Reports in Neurology
|
April 18, 2022
Late-Onset Pompe Disease Presenting with Isolated Tongue Involvement
Jasem Al-Hashel, Ismail Ismail
Multiple Sclerosis and Related Disorders
|
February 2, 2025
Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for Multiple Sclerosis: An observational registry-based study
Raed Alroughani, Jasem Al-Hashel, Samar Farouk Ahmed
Pediatric Neurology
|
September 19, 2015
Pediatric-Onset Multiple Sclerosis Disease Progression in Kuwait: A Retrospective Analysis
Raed Alroughani, Samar F Ahmed, Jasem Al-Hashel
Clinical Neurology and Neurosurgery
|
March 21, 2024
Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study
Raed Alroughani, Jasem Al-Hashel, Samar Farouk Ahmed
Neuroepidemiology
|
August 22, 2008
The prevalence of multiple sclerosis in the Middle East
Jasem Al-Hashel, Aaron D Besterman, Christina Wolfson
Multiple Sclerosis and Related Disorders
|
February 8, 2018
A longitudinal study of JC virus serostatus stability among multiple sclerosis patients
Raed Alroughani, Saeed Akhtar, Samar Ahmed, et al.
Case Reports in Neurological Medicine
|
May 14, 2014
An adult patient with ocular myasthenia and unusually long spontaneous remission
Jasem Al-Hashel, Hanaa M Rashad, Rossen T Rousseff
Multiple Sclerosis and Related Disorders
|
August 26, 2023
Real world study of ocrelizumab in multiple sclerosis: Kuwait experience
Raed Alroughani, Malak AlMojel, Jasem Al-Hashel, et al.
Page
of 5